Analysis of the human repertoire of the FK506-binding protein (FKBP) family of peptidyl-prolyl cis/ trans isomerases has identified an expansion of genes that code for human FKBPs in the secretory pathway. There are distinct differences in tissue distribution and expression levels of each variant. In this article we describe the characterization of human FKBP19 (Entrez Gene ID: FKBP11), an FK506-binding protein predominantly expressed in vertebrate secretory tissues. The FKBP19 sequence comprises a cleavable N-terminal signal sequence followed by a putative peptidyl-prolyl cis/trans isomerase domain with homology to FKBP12. This domain binds FK506 weakly in vitro. FKBP19 mRNA is abundant in human pancreas and other secretory tissues and high levels of FKBP19 protein are detected in the acinar cells of mouse pancreas.
Introduction
The synthesis, folding, and assembly of proteins involves some of the most essential and conserved mechanisms of life (Pahl et al. 1997 ). In eukaryotic systems, several families of chaperones and foldases have evolved to catalyze these processes (Fedorov and Baldwin 1997) . The folding of proline-containing polypeptides is catalyzed by peptidyl-prolyl cis/trans isomerases (PPIases; Fischer et al. 1984 ).
The PPIase families are classified by sequence homology and pharmacologically by their ability to bind the immunosuppressant compounds cyclosporin, FK506, and rapamycin and are otherwise known as immunophilins (reviewed in Galat and Riviere 1998; Galat 2003) . The FK506-binding protein (FKBP) family members share a high degree of sequence and structural homology and PPIase activity that is specifically inhibited by FK506 or rapamycin (Kay 1996) . Since the discovery of the first FKBP (Siekierka et al. 1989 ), several members of this family have been characterized in humans and other organisms (Patterson et al. 2002; Galat 2003) . Each member of the FKBP family contains one or more PPIase domains, which shows high sequence homology with the most abundant member, FKBP12.
Analysis of the genomes of eukaryotic model organisms shows correlations between genome size and the number of genes coding for FKBPs, with four members present in Saccharomyces cerevisiae, seven in Drosophila melanogaster, and nine in Caenorhabditis elegans (Kay 2000) . In general, eukaryotic organisms appear to have one or two FKBPs for every 2000 genes in their genome. If this pattern applied to the human genome, containing around 30,000 genes (Pennisi 2003) , there could be up to 30 FKBP sequences in the human genome. Although many cellular processes involving FKBPs may be conserved from lower organisms, degeneracy involving cyclophilins or parvulins as alternative PPIases may significantly reduce this predicted number. This report describes a survey of the human genome for FK506-binding proteins and the biochemical characterization of a novel member, FKBP19.
Methods
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Company Ltd., Poole, UK.
Cloning. IMAGE clones containing FKBP sequences were obtained from Research Genetics Inc. (Huntsville, AL, USA). These included IMAGE clone 269896 (accession numbers N24885 and N36303), which contained the full-length FKBP19 coding sequence, clone 323084 (accession number W42674), which contained a partial FKBP22 sequence, and clones 2518850 and 1857997 (accession numbers AI879695 and AI271550), which contained overlapping sequences covering the entire FKBP23 coding sequence. The FKBP23 clones shared a common internal StuI site. A BamHI-StuI fragment of the IMAGE clone 2518850 insert and a StuI-NotI fragment of clone 1857997 were generated. A three-way ligation of these two fragments with a BamHI-NotI digested pET21a expression vector produced a fulllength human FKBP23 clone.
Northern blotting. Probes were generated to the open reading frames (ORF) of each FKBP variant shown by PCR and radiolabeled with a-32 P dCTP using a Megaprime labeling kit (Amersham Pharmacia Biotech Ltd., Little Chalfont, UK). These were then used to probe a Human Multiple Tissue Northern and Human RNA Master Blot (Clontech, Mountain View, CA, USA) using ExpressHyb (Clontech), according to the recommended protocols. Washed blots were exposed to a phosphorimager screen (Molecular Dynamics, Sunnyvale, CA).
In vitro transcription/translation of hFKBP19. A full-length FKBP19 expression construct was generated by PCR and the resulting product was subcloned into pET21a using restriction sites incorporated into the primer sequences. The construct was then used as a template in the TNT-T7 Quick Coupled Transcription/Translation System (Promega UK Ltd., Southampton, UK). Translation products were radiolabeled with 35 S-methionine (Amersham Pharmacia Biotech Ltd.). Post-translational peptide cleavage was obtained by carrying out the coupled reaction in the presence of Canine Pancreatic Microsomal Membranes (Promega).
Expression constructs. Full-length expression constructs of FKBP19 and FKBP23 produced insoluble material in E. coli, so PCR primers (Genosys Biotechnologies Ltd., Cambridge, UK) were designed to amplify regions coding for the PPIase domain of human FKBP19 (GAGGCTGGGCTCGAAACCG and GCCCTTCACCAGCTTTAGCC) and the ''mature'' FKBP23 (complete ORF minus the first 24 amino acids, using primers 5¢-CCCATATGAGACA AAAGAAAGAGGAGAGC-3¢ and 5¢-CCCTCGAG TAGTTCATCGTGTTGGTATAC-3¢). An in-frame start codon was incorporated, where necessary, into PCR primers, as part of an NdeI site, and an XhoI site was incorporated at the 3¢ end, replacing the native stop codon. The resulting PCR fragment was cloned into pET21a (Novagen, Madison, WI, USA), such that the FKBP coding sequences were in-frame with a C-terminal His-tag sequence. A similar His-tagged expression construct was generated from the fulllength coding region of human USA-CYP for use as a negative control for binding studies as previously described (Pemberton et al. 2003 ). An FKBP13 expression construct was made for use as a positive control by amplifying a human FKBP13 fragment coding for the ''mature'', soluble form of the protein (i.e., the full length minus the first 21 amino acids) with primers 5¢-CCGAATTCACGGGGGCCGAG GGCAAAAGG-3¢ and 5¢-CCAAGCTTCAGCTCAG TTCGTCGCTCTAT-3¢. The fragment was subcloned into pET21a using the EcoRI and HindIII sites incorporated into the primer sequences.
Expression
and purification of human PPIases. BL21(DE3) cells (Novagen) transformed with each expression construct were grown in flasks and shaken at 200 rpm at 37°C in 2YT broth supplemented with 50 lg/ml ampicillin and 1% glucose. Expression was induced at an OD 600 of 0.8 with 1 mM IPTG. Cells were harvested 2.5 h after induction. Inclusion body preps were made from FKBP19-expressing E. coli as follows: 1 g of cells was lysed by sonication in 10 ml of 50 mM sodium phosphate (pH 7.0), 300 mM NaCl, 0.5 mM PMSF, and centrifuged at 1000g for 15 min to pellet inclusion bodies. These were washed twice in lysis buffer and resuspended in lysis buffer containing 6 M guanidine-HCl. After 4 h of mixing at 4°C, the samples were centrifuged again and the supernatant was added to 1 ml TALON resin (Clontech, Basingstoke, UK). After mixing at 4°C for 1 h, the resin was collected by centrifugation (1000g for 5 min), washed twice in 10 ml lysis buffer containing 6 M guanidine-HCl and three times in guanidine-free lysis buffer. Purified FKBP19 was eluted in 1-ml fractions with lysis buffer containing 150 mM imidazole.
His-tagged FKBP23 was purified as described above except that the protein was purified from the soluble fraction of the cell lysate and no guanidineHCl was used at any stage. FKBP13 was purified on SP Sepharose resin in 50 mM Bis-Tris propane buffer at pH 9 with a 0À1 M NaCl gradient. Fractions giving the correct size band were dialyzed into 50 mM Tris, 200 mM NaCl, pH 7.4. Human USA-CYP was purified as described (Pemberton et al. 2003 ).
Antibodies and Western blotting. Protein products and in vitro translation products were separated by SDS-PAGE using precast 4%À20% Tris-glycine gels (Invitrogen, Carlsbad, CA, USA) and transferred to PVDF membrane (Invitrogen). Blots were blocked in 5% dried milk for 1 h, incubated with primary antibody/1% milk in phosphate buffered saline (PBS) for 2 h, washed in PBS/0.1% Tween-20 three times, incubated in secondary antibody/1% milk for 1 h, and washed five times in PBS/0.1% Tween-20. Blots were developed using BCIP/NBT liquid substrate system (Sigma).
For analysis of tagged protein expression in in vitro translation products and E. coli extracts, an alkaline phosphatase-conjugated monoclonal anti-T7 antibody was used (Novagen) and incubation with secondary antibody was not necessary. For analysis of native protein expression in bovine and mouse extracts, a rabbit polyclonal antibody was generated to the full-length tagged protein product by Cambridge Research Biochemicals. The specificity of this antibody was further improved by purifying PPIase-domain-binding species in the immunized rabbit serum using a Hi-Trap NHSactivated column (Amersham) containing conjugated FKBP19 PPIase domain. An alkaline phosphatase-conjugated anti-rabbit IgG antibody was used as a secondary antibody. H-FK506-binding assay. The FK506-binding assay (Siekierka et al. 1990 ) was carried out in individual 1-ml columns prepacked with LH20 medium (Amersham Pharmacia Biotech Ltd.) and equilibrated in assay buffer (50 mM Tris-HCl, pH 7.4, 200 mM NaCl). FKBP (1 lM) was incubated with 12 nM 3 Hdihydro-FK506 (NEN Life Science Products, Hounslow, UK) for 25 min at room temperature before being applied to the column. One-hundred-microliter fractions were eluted in assay buffer and counted for 10 min in a Beckman LS 6000IC scintillation counter.
Immunohistochemistry. Adult C3H mouse pancreas was fixed in 10% buffered formaldehyde and embedded in paraffin wax. Five-micron-thick sections were obtained and de-paraffinised in xylene substitute and graded ethanol solutions. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in isopropanol.
For FKBP19 labeling, the sections were microwaved in 10 mM citrate buffer (pH 6.0) and rinsed with PBS at room temperature. To inhibit the nonspecific endogenous biotin staining, the Dako Blocking System (Dako, Glostrup, Denmark) was used. A blocking solution of 10% swine serum (Dako) was used for 10 min. Polyclonal anti-FKBP19 was used at a dilution of 1:100 for 1 h at room temperature. Biotinylated swine anti-rabbit antibody (Dako) and ChemMate Detection Kit (Dako) were used to develop the specific signals. The negative control specimen was incubated in swine serum and processed identically.
For insulin labeling, the sections were rinsed with PBS, blocked with 10% rabbit serum, and incubated with polyclonal guinea pig anti-insulin (Dako) at a dilution of 1:500 for 1 h at room temperature. Peroxidase-conjugated rabbit anti-guinea pig (Dako) and diaminobenzidine (Dako) were used to develop the signals. The negative control specimen was incubated in rabbit serum and processed identically. All slides were counterstained with hemotoxylin.
Results
Fifteen FKBP sequences have been identified in the human genome (Table 1) . Only genes where ESTderived sequences are available are included here. Reference to hFKBP-12c (described by Galat 2003 ) is omitted from these data since no expressed sequences corresponding to this predicted sequence were found. The FKBP family can be subdivided into four groups by classification of the regions within or surrounding the conserved PPIase domains (Fig. 1) . In humans there are multiple subtypes within each of these groups. Each subtype may bind different subcellular targets as a result of subtle differences in their sequences. The four mammalian FKBP subgroups comprise the cytoplasmic, nuclear, TPRdomain, and secretory-pathway 
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. Calciumbinding EF-hand (interpro ID 002048) motifs are also present in the C-terminal region of several of these proteins. The PPIase domains of this class of proteins can be identified by the presence of two cysteine residues, which are thought to form a disulfide bond in the oxidizing environment of the ER and stabilize the tertiary structure of the PPIase domain (Jin et al. 1991 ). Other typical features of this group are the presence of two basic amino acids that are four residues downstream of the second cysteine residue and a conserved proline that are five residues thereafter (Fig. 2) . FKBP19 (accession number AF238079) represents a previously uncharacterized FKBP subtype. The 740-bp human FKBP19 cDNA sequence is derived from six exons on Chromosome 12 and contains an ORF coding for a 22-kDa protein with some unique features. Highly conserved FKBP19 orthologs are present in other vertebrates (Fig. 3) but none have been found in invertebrate species.
A 4-kb region of Chromosome 12 that lies immediately upstream of FKBP19 was found in the Ensembl database and scanned for putative transcription factor binding sites using the Biobase Match TM tool (Goessling et al. 2001 ). Five putative NKX2-5 and four Pax4 binding sites were found in this region, suggesting a role in the pancreas (Inoue et al. 1998 ). Analysis of EST sequences showed that FKBP19 is highly expressed in melanocytes and placenta but is also expressed in pancreatic islet cell, senescent fibroblast, and breast libraries. A radiolabeled FKBP19 probe showed a transcript of approximately 800 bp expressed at high levels in human pancreatic tissue, with low expression levels in the other seven tissues probed and very low levels in brain (Fig. 4, left panel) . High levels of expression in the pancreas and other secretory tissues, such as stomach, pituitary gland, salivary gland, and lymph node, were confirmed by probing a dot blot containing messenger RNA extracted from 50 different human tissues (Fig. 4, right panel) . In contrast, FKBP22 and the two FKBP23 variants show low levels of expression in the secretory tissues and relatively higher levels in the heart. However, differences between the expression levels of FKBP22 and the FKBP23s in the brain, for example, show that these members of the FKBP family also exhibit tissue-specific expression.
The FKBP domain of FKBP19 sequence demonstrates 38% amino acid identity with FKBP12 and 46% with the FK506-binding domain of FKBP13. It contains some of the features typical of secretorypathway FKBPs, such as the two cysteine residues, and also a conserved basic motif and subsequent proline residue shortly after the second cysteine (Fig. 2) . The FKBP domain of FKBP19 binds FK506 in an in vitro binding assay and shows binding of FK506 over nonspecific binding by a structurally unrelated PPIase USA-CYP (Horowitz et al. 1997 ). However, FKBP13 binds over 200 times as much FK506 in the same assay, whereas the binding of 32 P-labeled probe generated from the coding sequences of FKBP19, FKBP22, or FKBP23. Approximate sizes of transcripts are shown on the left. Lanes represent mRNA isolated from (1) heart, (2) brain, (3) placenta, (4) lung, (5) liver, (6) skeletal muscle, (7) kidney, (8) pancreas. (Right) Results obtained by using the FKBP19-specific probe with a Clontech human mRNA Master Blot, which contains normalized RNA samples from 42 different human tissues: A1À8: whole brain, amygdala, caudate nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus, medulla oblongata; B1À7: occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, subthalamic nucleus, spinal cord; C1À8: heart, aorta, skeletal muscle, colon, bladder, uterus, prostate, stomach; D1À8: testis, ovary, pancreas, pituitary gland, adrenal gland, thyroid gland, salivary gland, mammary gland; E1À8: kidney, liver, small intestine, spleen , thymus, peripheral leukocyte, lymph node, bone marrow; F1À4: appendix, lung, trachea, placenta; G1À7: fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, fetal lung; H7À8: human gDNA 100 ng, human gDNA 500 ng. FK506 by FKBP23 is not detectable over nonspecific binding (Fig. 5) .
Other features of FKBP19 include a leucine-rich N-terminal leader sequence of 25 residues, which shows similarities with other known secretorypathway proteins (von Heijne 1983). Cleavage at the predicted site of 3 kDa would leave a 19-kDa mature protein, thus named FKBP19. The C-terminus of this protein differs from the other secretory-pathway FKBPs in that it lacks a calcium-binding EF-hand that is typical of several other secretory pathway FKBPs and contains a putative transmembrane domain (as predicted by PSORT; Nakai and Horton 1999), followed by a lysine-rich C-terminal tail containing a variant of the di-lysine motif found in ER-membrane proteins (Teasdale and Jackson 1996) .
An antibody raised to the PPIase domain of FKBP19 recognized recombinant FKBP19 but not the closely related PPIases FKBP12.6 and FKBP23 (Fig. 6A) . Affinity chromatography to an FKBP19-conjugated column completely abolished detectable antibody binding, showing that the antiserum is specific to FKBP19 (Fig. 6B) . Anti-FKBP19 detects a doublet of 19À22 kDa in bovine pancreas extracts (Fig. 6D) . This is likely to be a mixed population of proteins containing cleaved and uncleaved N-termini. This is supported by the loss of approximately 3 kDa in an in vitro reaction in the presence of canine pancreatic microsomes (Fig. 6E) . Immunohistochemical analysis of FKBP19 production in the mouse pancreas shows high levels of FKBP19 protein, localized throughout the cytoplasmic region of acinar cells and concentrated in the perinuclear region of these cells (Fig. 7A, C) . Low levels are seen in the islets of Langerhans, which were confirmed by immunolabeling with an antibody directed to insulin (Fig. 7D ).
Discussion
Analysis of human genome sequence data has confirmed previous reports that there are 15 different FKBP variants expressed in human tissues. It seems likely that this number represents the complete human FKBP repertoire, although splice variation in those such as FKBP23 may increase the number of different functional FKBPs.
The conserved sequences of the PPIases suggest that their cellular targets may overlap. Common partners of TPR-containing PPIases have been demonstrated previously (Ratajczak and Carrello 1996) . Tissue-specific expression profiles, such as that shown for FKBP19 above, and the separation of multiple subtypes by subcellular localization signals (Fig. 1 ) may be sufficient to avoid much of the erroneous binding by promiscuous members of this family. However, the overlapping expression profiles and subcellular localization of FKBPs in the secretory pathway suggest that regulation of expression and protein sorting is not enough. This raises the question of why multiple isoforms are so highly conserved between species if they are involved in degenerate pathways. Alternatively, subtle differences in the primary sequence of a protein could lead to dramatic differences in its affinity for a target. This hypothesis is supported by the differential binding abilities of three similar secretory-pathway FKBPs for the exogenous ligand FK506. However, a third explanation could be that sequence divergence is required for tertiary structure and functionality in a wide range of cellular environments. The presence of a disulfide bond in the FKBP domain appears to be necessary for all of the human FKBPs in the secretory pathway. Extremes in pH and oxidative or ionic strength in tissues such as the pancreas may be why specialized molecules are required for functional protein production and transport in these tissues. pH-dependent activity has been demonstrated for other PPIases (Ranganathan et al. 1997 ).
There appears to be a wider expansion of secretory FKBPs in vertebrates compared to other animals. Analysis of genomic models shows that S. ccerevisae has only one FKBP in the secretory pathway, whereas Schizosaccharomyces pombe has none at all. There are two present in the Drosophila genome, and up to five in C. elegans (Kay 2000) . This report confirms that at least six secretorypathway FKBPs are present in vertebrates: FKBP13, FKBP22, FKBP23 (isoforms a and b), FKBP60, and FKBP65 represent closely related variants of the FKBPs in the ER lumen, although FKBP13 lacks the calcium-binding region of the other members of this group. These probably have similar functions in folding proteins in the bulk flow of the ER of these tissues, as previously suggested for FKBP13 (Bush et al. 1994 ). FKBP19 represents a highly conserved unique FK506-binding protein, which so far appears to be unique to vertebrate genomes. Unlike FKBP65 (Patterson et al. 2000) . FKBP19 does not appear to be developmentally regulated and is expressed at low levels in many fetal and adult tissues. FKBP19 may be bound to the membrane of secretory microsomes and expression appears to be elevated in tissues with exocrine properties. Highly tissue-specific PPIases have been previously reported: For example, the cyclophilin protein ninaA is specifically expressed in the photoreceptor cells of Drosophila and is required for the production of rhodopsin (Baker et al. 1994 ). The expression profile of FKBP19 suggests that its role may have a unique role in protein secretion. Identification of cellular targets would be required to confirm this hypothesis. 
